^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    RG6596

    i
    Other names: RG6596, ZN-A-1041, ZN-1041, RG 6596, ZN 1041, ZN A 1041, RG-6596, ZN1041, ZNA1041
    Company:
    Roche, Suzhou Zanrong
    Drug class:
    HER2 inhibitor
    Related drugs:
    4ms
    A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Patients With HER2-Positive Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=210, Recruiting, Suzhou Zanrong Pharma Limited | Trial completion date: Oct 2024 --> Oct 2026 | Trial primary completion date: Oct 2023 --> Oct 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    HER-2 positive
    |
    Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • RG6596
    over1year
    Trial of ZN-A-1041 Enteric Capsules in Patients With HER2-Positive Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=84, Recruiting, Suzhou Zanrong Pharma Limited | Trial primary completion date: Dec 2022 --> Dec 2023
    Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • capecitabine • RG6596
    4years
    Trial of ZN-A-1041 Enteric Capsules in Patients With HER2-Positive Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=84, Recruiting, Suzhou Zanrong Pharma Limited | Not yet recruiting --> Recruiting
    Clinical • Enrollment open • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    capecitabine • RG6596
    over4years
    Trial of ZN-A-1041 Enteric Capsules in Patients With HER2-Positive Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=84, Not yet recruiting, Suzhou Zanrong Pharma Limited
    Clinical • New P1 trial • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    capecitabine • RG6596